Director McCracken bought 10,000 shares of SVRA at $2.08 on 2025-05-29; holds 260.8K shares post-transaction in unprofitable biotech.
McCracken Joseph S, a Director, purchased 10,000 shares at $2.08 on 2025-05-29, increasing his holdings by 4.0% to 260.8K shares. The stock has declined 29.4% in the 30 days since the transaction and is now trading at $2.40, down 52.7% from its 52-week high of $5.07. Savara Inc is a revenue-generating company (latest quarter revenue $0.00) with a net loss of $26.6M and negative full-year earnings, indicating material operational headwinds. McCracken's cross-ticker buy track record shows 1 prior purchase with a 90-day return of -4.5%, and this same-ticker pattern repeats: his prior SVRA buy on 2024-11-19 also yielded -4.5% over 90 days, with a 0% win rate on timing such buys.
Director Joseph McCracken bought 20,000 SVRA shares at $2.95 on 2024-11-19; now holds 210,837 shares.
McCracken purchased 20,000 shares at $2.95, expanding his position by 10.5% to 210,837 shares total. The transaction occurred at a price point near the 52-week low of $2.94, with the stock currently trading at $3.13 and substantially depressed from its $5.59 high. Savara is a loss-making company with $-24.2M net income in its most recent full fiscal year and zero revenue in the latest quarter, indicating a development-stage or pre-revenue business model. The buy at near-52-week-low pricing by a director with meaningful historical stake represents notable insider accumulation in a fundamentally challenged entity, warranting scrutiny of the strategic rationale and broader board conviction about the company's prospects.
